HDAC/JAK/BRD4-IN-1

SI-7395

HDAC/JAK/BRD4-IN-1, >98% (HPLC)

CAS No. : [2755325-84-7]

IUPAC Name : N-Hydroxy-4-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a Fedratinib‑derived HDAC/JAK/BRD4 triple inhibitor that simultaneously blocks HDACs and the BRD4–LIFR–JAK1–STAT3 pathway. In TNBC cells, it drives histone/α‑tubulin hyperacetylation, reduces STAT3 phosphorylation, and downregulates LIFR, MCL‑1, and c‑Myc, resulting in potent antiproliferative and pro‑apoptotic activity. It shows an acceptable therapeutic window, good metabolic stability, sufficient in vivo exposure, and clear xenograft antitumor efficacy, supporting its promise as a multitarget TNBC lead.

References : Zhao C. et al.: J. Med. Chem., 66(20), 14150-14174, 2023.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.